Article Dans Une Revue Frontiers in Oncology Année : 2021

Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients

Résumé

Although salvage prostate bed radiotherapy is highly effective in biochemically-relapsing prostate cancer patients following prostatectomy, relapses remain frequent and improvements are needed. Randomized phase 3 trials have shown the benefit of adding androgen-depriving therapy to irradiation, but not all patients benefit from this combination. Preclinical studies have shown that novel agents targeting the androgen receptor, DNA repair, PI3K/AKT/mTOR pathways, or the hypoxic microenvironment may help increase the response to prostate bed irradiation while minimizing potential side effects. This perspective review focuses on the most relevant molecules that may have an impact when combined with salvage radiotherapy, and underlines the strategies that need to be developed to increase the efficacy of salvage post-prostatectomy radiotherapy in prostate cancer patients.

Fichier principal
Vignette du fichier
fonc-11-780507.pdf (400.11 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04932165 , version 1 (06-02-2025)

Licence

Identifiants

Citer

Axel Cailleteau, Paul Sargos, Fred Saad, Igor Latorzeff, Stéphane Supiot. Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, pp.780507. ⟨10.3389/fonc.2021.780507⟩. ⟨hal-04932165⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More